Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engert

Showing results (51-60 of 173) with videos related to

Pageof 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectivesJ Wolf, H Tesch, R Parsa-Parsi, et al.
Journal of Neuro-Oncology|September 21, 2002
Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximabH Pels, H Schulz, O Manzke, et al.
The Cochrane Database of Systematic Reviews|February 7, 2008
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adultsA Greb, J Bohlius, D Schiefer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2019
Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trialsS Borchmann, H Müller, I Hude, et al.
International Journal of Cancer|September 30, 1991
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in miceA Engert, G Martin, P Amlot, et al.
Blood|August 15, 2000
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study GroupA Josting, U Rueffer, J Franklin, et al.
Journal of Molecular Biology|September 1, 2000
Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage displayS Barth, U Weidenmüller, M K Tur, et al.
Blood|September 25, 1999
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)U Winkler, M Jensen, O Manzke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?A Josting, M Reiser, U Rueffer, et al.
Annals of Hematology|January 25, 2002
Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II studyM Uppenkamp, A Engert, V Diehl, et al.
Pageof 18

Showing results (51-60 of 173) with videos related to

Sort By:
Pageof 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectivesJ Wolf, H Tesch, R Parsa-Parsi, et al.
Journal of Neuro-Oncology|September 21, 2002
Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximabH Pels, H Schulz, O Manzke, et al.
The Cochrane Database of Systematic Reviews|February 7, 2008
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adultsA Greb, J Bohlius, D Schiefer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2019
Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trialsS Borchmann, H Müller, I Hude, et al.
International Journal of Cancer|September 30, 1991
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in miceA Engert, G Martin, P Amlot, et al.
Blood|August 15, 2000
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study GroupA Josting, U Rueffer, J Franklin, et al.
Journal of Molecular Biology|September 1, 2000
Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage displayS Barth, U Weidenmüller, M K Tur, et al.
Blood|September 25, 1999
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)U Winkler, M Jensen, O Manzke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?A Josting, M Reiser, U Rueffer, et al.
Annals of Hematology|January 25, 2002
Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II studyM Uppenkamp, A Engert, V Diehl, et al.
Pageof 18